Access to Hepatitis C treatment
through state AIDS Drug Assistance Programs (ADAPs)
TAG's Coinfection Project Director, Tracy Swan, looks at access to hepatitis C treatment through State ADAPs.

TAG's Hepatitis/HIV Project Director, Tracy Swan, looks at access to hepatitis C treatment through State ADAPs. Access to hepatitis C treatment is crucial for HIV/HCV co-infected people. Although hepatitis C can be treated, regardless of a person's HIV status, HCV-associated end-stage liver disease has become a leading cause of death among HIV-positive people in the US.

The Henry J. Kaiser Family Foundation and the National Alliance of State and Territorial AIDS Directors (NASTAD) released the 2008 National ADAP Monitoring Project Annual Report on April 8th, 2008, which is the source of this data.

Although funding shortfalls and increasing need mean that the majority of ADAPs are currently unable to provide pegylated interferon and ribavirin, some are able to cover HCV treatment and/or adjunctive therapies used to manage side effects (see table of State ADAP Coverage, below). Some State ADAPs offer hepatitis A (HAV) and hepatitis B (HBV) vaccines, which are recommended for people with HIV and hepatitis C who are susceptible to these viruses.

If your State ADAP does not cover hepatitis C treatment, you may be able to obtain it through patient assistance programs sponsored by Roche and Schering (accessed on April 6 2008).
STATE ADAP COVERAGE: HEPATITIS A (HAV) & HEPATITIS B (HBV) VACCINES, HEPATITIS C TREATMENT, GROWTH FACTORS, & SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) as of June 2007
STATEIFN (PEG, Standard, Consensus)RBVSSRIs/Other*EPOETIN-ALFAFILGRASTIMHAV & HBV VACCINEWAITING LIST/Other Cost Containment
ALABAMAPEG-IFNX
X

capped enrollement
ALASKAPEG-IFNX


X
ARIZONAPEG-IFNXXXXX
ARKANSAS
CALIFORNIAStandard IFNXXXXX
COLORADO
X
CONNECTICUTPEG-IFN X X
X X
DELAWAREPEG-IFNXXXX X
DISTRICT OF COLUMBIAPEG-IFNXX
FLORIDA

X
XX
GEORGIA
HAWAII

XXX
IDAHO





Cost containment anticipated before 3/31/09
ILLINOISPEG IFN



X
INDIANA

X

XCost containment anticipated before 3/31/09
IOWAPEG-IFNXX
KANSAS

X
KENTUCKY




XCost containment anticipated before 3/31/09
LOUISIANA
MAINEPEG-IFN, Standard IFNXX

X
MARYLANDPEG-IFNXXXX
MASSACHUSETTSAll FDA approved drugs are covered**
MICHIGANPEG-IFN, Standard IFNXXXXXFormulary management
MINNESOTA

X
MISSISSIPPIPEG-IFN XX

X
MISSOURI

X

X
MONTANA

XXX
Waiting list
NEBRASKA

X



NEVADA

X
 X

NEW HAMPSHIRE All FDA approved drugs are covered**
NEW JERSEYAll FDA approved drugs are covered**
NEW MEXICO

X

X
NEW YORKPEG-IFN, Standard IFNXXXXX
NORTH CAROLINA

X



NORTH DAKOTA PEG-IFN
X X X
OHIO

X
X X
OKLAHOMA
OREGONAll FDA approved drugs are covered**
PENNSYLVANIA PEG-IFN X
X
X
PUERTO RICOPEG-IFN, Standard IFNXXXX
RHODE ISLANDStandard IFNXX
SOUTH CAROLINA

X


Cost containment anticipated before 3/31/09
SOUTH DAKOTA

X

X
TENNESSEE
 X X
X

TEXASStandard IFN
U.S. Virgin Islands





Client cost sharing; additional cost containment anticipated by 3/31/08
UTAHPEG-IFNX

X
VERMONT

X X X X
VIRGINIA PEG-IFN X X X
X
WASHINGTONPEG-IFN, Standard IFN X X X X X
WEST VIRGINIA




X
WISCONSINPEG-IFN X X

X
WYOMING
X X

X

* May include anti-anxiety agents, anti-depressants, anti-psychotics, mood stabilizers, and other psychiatric medications.
** With certain exclusions.
Source: Henry J. Kaiser Family Foundation, National Alliance of State and Territorial AIDS Directors (NASTAD). National ADAP Monitoring Project, Annual Report, April 2008. ADAP Formularies. Available on-line at: http://www.kff.org/hivaids/7746.cfm (accessed on April 14, 2008).

Thanks to Britten Ginsburg, Murray Penner, Beth Crutsinger-Perry and Chris Taylor at NASTAD for making this resource possible.

Hepatitis C Coinfection Project
TAG index